Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer

Abstract

Introduction Breast cancer is the main reason for cancer-related deaths in women and the most common malignant cancer among women. In recent years, immunosuppressive factors have become a new type of treatment for cancer. However, there are no effective biomarkers for breast cancer immunotherapy. Therefore, exploring immune-related biomarkers is presently an important topic in breast cancer. Methods Gene expression profile data of breast cancer from The Cancer Genome Atlas (TCGA) was downloaded. Scale-free gene co-expression networks were built with weighted gene co-expression network analysis. The correlation of genes was performed with Pearson’s correlation values. The potential associations between clinical features and gene sets were studied, and the hub genes were screened out. Gene Ontology and gene set enrichment analysis were used to reveal the function of hub gene in breast cancer. The gene expression profiles of GSE15852, downloaded from the Gene Expression Omnibus database, were used for hub gene verification. In addition, candidate biomarkers expression in breast cancer was studied. Survival analysis was performed using Log rank test and Kaplan–Meier. Immunohistochemistry was used to analyze the expression of CCNA2 . Results A total of 6 modules related to immune cell infiltration were identified via the average linkage hierarchical clustering. According to the threshold criteria (module membership >0.9 and gene significance >0.35), a significant module consisting of 13 genes associated with immune cells infiltration were identified as candidate hub genes after performed with the human protein interaction network. And 3 genes with high correlation to clinical traits were identified as hub genes, which were negatively associated with the overall survival. Among them, the expression of CCNA2 was increased in metastatic breast cancer compare with non-metastatic breast cancer, who underwent immunotherapy. Immunohistochemistry results showed that CCNA2 expression in carcinoma tissues was elevated compared with normal control. Discussion CCNA2 identified as a potential immune therapy marker in breast cancer, which were first reported here and deserved further research.

Predicting prognosis and clinical features of the tumor microenvironment based on ferroptosis score in patients with breast cancer

“…Basic research in areas such as tumor genomics, RNA-omics, and proteomics is expanding application in clinical practice. Molecular pathological diagnosis is becoming increasingly important for early diagnosis, drug efficacy evaluation, and prognostic testing of BRCA, gradually changing the traditional empirical treatment model to an individual-body treatment model based on biomarkers [32][33][34] .…”

Characterization of Cell Cycle-Related Competing Endogenous RNAs Using Robust Rank Aggregation as Prognostic Biomarker in Lung Adenocarcinoma

“…Herein, based on an integrative analysis of diverse RNAs from different datasets, CCNA2/MKI67/KIF11:miR-30a-5p: VPS9D1-AS1 axis-related cell cycle is identified as a potential prognostic marker via constructing a ceRNA network and indepth analysis, and all of them are characterized as crucial RNAs in the occurrence and development of LUAD. Of the three mRNAs, CCNA2 has been studied because of its role in cancer, including its prognostic value in breast cancer (54)(55)(56), colorectal cancer (57), pancreatic cancer (58), LUAD (59), gastric cancer (60), bladder cancer (61), etc. MKI67, a marker gene in the cell cycle, also has been reported with prognostic value in NSCLC (62) and breast cancer (63).…”

Role of ferroptosis-related genes in coronary atherosclerosis and identification of key genes: integration of bioinformatics analysis and experimental validation

“…CCNA2 is over-expressed in a variety of human malignancies, suggesting its potential role in cancer transformation and progression. The study found that CCNA2 expression was significantly high in carcinoma tissues than in normal controls, and CCNA2 was considered as a potential immunotherapy marker in breast cancer [ 17 ]. Meanwhile, some studies have shown that CCNA2 can be used for the early detection and prognosis of colon cancer [ 18 ].…”